Moleculin Biotech filed a certificate to effect a 1-for-20 reverse stock split effective October 20, 2026, amid efforts to meet Nasdaq listing requirements. No shares were sold and capital was not raised.
Moleculin Biotech filed a certificate to effect a 1-for-20 reverse stock split effective October 20, 2026, amid efforts to meet Nasdaq listing requirements. No shares were sold and capital was not raised.